Among children, adolescents and adults with peanut allergy, a once-daily peanut sublingual immunotherapy tablet was well tolerated up to the highest dose in an up-dosing regimen, according to phase ...

Daily peanut oral immunotherapy enabled children with high-threshold peanut allergies to achieve full tolerance. Of the treated children, 68.4% tolerated a meal-size dose of peanut protein versus 8.6% ...

Cork University Hospital is the only public hospital offering the treatment under a pilot programme, Dáil committee heard ...

SAN DIEGO ‑- Off-the-shelf peanut products used in oral immunotherapy for peanut allergies contain a wide range of protein and allergen levels -- even products in a single lot, researchers said here.

Children with peanut allergy who achieved remission with sublingual immunotherapy (SLIT) had lower basophil activation before treatment and greater suppression of basophils at 1 year than those who ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Peanut protein tolerance at 1 year was similar between ...

The first clinical trial to test whether adults allergic to peanuts can be desensitized has shown great success with two thirds of the cohort consuming the equivalent of five peanuts without reacting.

ORLANDO (Nov. 6, 2025) – New research presented at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) offers encouraging news for parents of young ...

Early introduction to a range of foods, including potential allergens, remains the best way to help prevent food allergies in infants and young children, and options for treatment are in the pipeline, ...

A man with a life-threatening allergy to peanuts overcame it through a new clinical trial that exposed people to small, supervised doses of the allergen. Now, he eats peanuts for breakfast. Chris ...

DBV Technologies (NASDAQ:DBVT) outlined its late-stage plans for VIASKIN Peanut and its broader epicutaneous immunotherapy platform during a presentation at the Citizens Life Sciences Conference, with ...